if for example BD1 licensed the use of AI tech from LBT, a module could feasibly be approved in months & then on licensed to VHT (breast density software provider covering 32% of the US market), the roll out to the majority of US women could be quite seamless - and if they are able to improve the histopatholgy accuracy to 100% (from between 50-75%) this is huge huge. all of the LBT modules work by identifying positives and having a human pathologist review. the academic journals discussing the mis classification on histopatholgy breast samples recommend samples are reviews always by 2 pathologists however - this is limited by availability of pathologist time.
if for example BD1 licensed the use of AI tech from LBT, a...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
61.5¢ |
Change
-0.018(2.77%) |
Mkt cap ! $67.82M | |||
| Open | High | Low | Value | Volume |
| 63.0¢ | 64.5¢ | 61.5¢ | $56.40K | 89.59K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10016 | 61.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 4900 | 1 |
View Market Depth
| Last trade - 15.16pm 02/08/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |